


# Super-Obese Patient-Derived iPSC Hypothalamic Neurons Exhibit Obesogenic Signatures and Hormone Responses

## Graphical Abstract



## Authors

Uthra Rajamani, Andrew R. Gross, Brooke E. Hjelm, ..., Allen M. Andres, Roberta A. Gottlieb, Dhruv Sareen

## Correspondence

dhruv.sareen@cshs.org

## In Brief

Human hypothalamic neurons (HTNs) implicated in obesity have a limited availability. This study describes a reliable method for generating functional hormone-responsive HTNs from multiple normal and obese patient reprogrammed hiPSCs. Obese-patient-induced HTNs retained transcriptome profiles and functional phenotypes of high BMI, exhibiting aberrant obesity-related metabolic and respiratory pathways.

## Highlights

- Obesity-associated coding variants are detected in super-obese hiPSCs
- Super-obese iHTNs retain dysregulated obesogenic disease signatures
- Impaired respiratory function and ghrelin-leptin signaling exist in super-obese iHTNs
- Ghrelin and leptin exacerbate orexigenic response of super-obese iHTNs



# Super-Obese Patient-Derived iPSC Hypothalamic Neurons Exhibit Obesogenic Signatures and Hormone Responses

Uthra Rajamani,<sup>1,2</sup> Andrew R. Gross,<sup>1</sup> Brooke E. Hjelm,<sup>3</sup> Adolfo Sequeira,<sup>3</sup> Marquis P. Vawter,<sup>3</sup> Jie Tang,<sup>4</sup> Vineela Gangalapudi,<sup>4</sup> Yizhou Wang,<sup>4</sup> Allen M. Andres,<sup>5,6</sup> Roberta A. Gottlieb,<sup>5,6</sup> and Dhruv Sareen<sup>1,2,7,8,9,\*</sup>

<sup>1</sup>Board of Governors, Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

<sup>2</sup>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

<sup>3</sup>Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA 92868, USA

<sup>4</sup>Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

<sup>5</sup>Metabolism and Mitochondrial Research Core, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

<sup>6</sup>Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

<sup>7</sup>Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA

<sup>8</sup>iPSC Core, The David Janet Polak Foundation Stem Cell Core Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

\*Correspondence: [dhruv.sareen@cshs.org](mailto:dhruv.sareen@cshs.org)

<https://doi.org/10.1016/j.stem.2018.03.009>

## SUMMARY

The hypothalamus contains neurons that integrate hunger and satiety endocrine signals from the periphery and are implicated in the pathophysiology of obesity. The limited availability of human hypothalamic neurons hampers our understanding of obesity disease mechanisms. To address this, we generated human induced pluripotent stem cells (hiPSCs) from multiple normal body mass index (BMI; BMI  $\leq$  25) subjects and super-obese (OBS) donors (BMI  $\geq$  50) with polygenic coding variants in obesity-associated genes. We developed a method to reliably differentiate hiPSCs into hypothalamic-like neurons (iHTNs) capable of secreting orexigenic and anorexigenic neuropeptides. Transcriptomic profiling revealed that, although iHTNs maintain a fetal identity, they respond appropriately to metabolic hormones ghrelin and leptin. Notably, OBS iHTNs retained disease signatures and phenotypes of high BMI, exhibiting dysregulated respiratory function, ghrelin-leptin signaling, axonal guidance, glutamate receptors, and endoplasmic reticulum (ER) stress pathways. Thus, human iHTNs provide a powerful platform to study obesity and gene-environment interactions.

## INTRODUCTION

The hypothalamus, a region caudal to the thalamus and constituting about 0.3% of the adult human brain (MacLean, 1968), regulates the autonomic nervous and endocrine systems. The hypothalamus secretes various neurotransmitters, neuropeptides, and neurohormones that play critical roles in maintaining homeostatic processes in reproduction, stress, immune function, circadian rhythm, and energy metabolism (Utiger, 2017). Neurons of the arcuate nucleus (ARC) in the hypothalamus express pro-opiome-

lanocortin (POMC), agouti-related peptide (AgRP), cocaine- and amphetamine-regulating transcript (CART), and neuropeptide Y (NPY), all of which respond to peripheral signaling hormones, including insulin, leptin, peptide YY (PYY), and ghrelin. By secreting neuropeptides such as NPY and  $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ -MSH) (Wang et al., 2015), the hypothalamus in the CNS coordinates responses to hunger and satiety signals and determines food intake or expenditure.

Obesity is a global epidemic and a grave public health concern as the prevalence of obesity has more than doubled since 1970s and due to its comorbidity with several other cardiovascular risk factors, including high blood pressure and cholesterol levels, which often lead to coronary heart disease and stroke. Type 2 diabetes, sleep apnea, breathing problems, gallbladder disease, and certain cancers, are also linked to higher body mass index (BMI). With close to 200 genetic variants identified, in the majority of the population, obesity is polygenic where multiple genetic variants that are common and have small effects contribute to obesity susceptibility. Many of these genes regulate food intake and expenditure, energy metabolism, calorie burning efficiency, and how fat and sugar are metabolized resulting in body fat deposition. Given the role of the hypothalamus in feeding regulation, recent genome-wide association studies (GWASs) have also indicated a significant representation of CNS and hypothalamic processes in determining the BMI and regulation of obesity (Locke et al., 2015). Several of the BMI loci previously identified are located near genes expressed in the brain and CNS, specifically those involved in signaling pathways associated with clathrin-coated vesicles, decreased neurotransmitter release, glutamate signaling, synapse biology, and the generation of hormonal signals. Mutations in hypothalamic-specific genes, such as *POMC* and melanocortin 4 receptor (MC4R), in monogenic obesity syndromes also bolster the notion that the hypothalamus is a central coordinator of obesity and energy metabolism pathways in humans. Unfortunately, despite the great need for relevant neuronal models for obesity research, the relative inaccessibility of the hypothalamus tissue has precluded the collection of live cells from human subjects.



The use of human induced pluripotent stem cells (hiPSCs), however, obviates the need for direct collection by allowing the generation of hypothalamic-like neuronal cultures (iPSC-derived hypothalamic-like neurons [iHTNs]) from blood or fibroblasts of healthy and obese subjects to investigate the mechanisms of metabolic dysregulation impacting the CNS. To address this shortcoming, we employed hiPSCs generated from super-obese (BMI  $\geq$  50) and normal (BMI  $\leq$  25) subjects, and we differentiated them to hypothalamic-like neuronal cultures. Importantly, these iHTNs exhibited characteristics and functions of the human hypothalamic ARC, and they resembled phenotypically human hypothalamus tissue with responsiveness to exogenous hormonal signals, which was not demonstrated in previous studies that differentiated hiPSCs to hypothalamic-like neurons.

In this study, we identified that reliable generation of iHTNs required carefully timed and dose-dependent small molecule-assisted modulation of mothers against decapentaplegic (Smad) pathway inhibition, sonic hedgehog (Shh) activation, wingless-type MMTV integration site (Wnt) family, and Notch-signaling inhibition. Notably, we identified dysregulated obesity genes in differentiated iHTNs from super-obese patients with polygenic coding variants and that they retain the dysregulated obesogenic transcriptome-level profiles. This stem cell model demonstrates retention of obesogenic disease signatures in human iHTNs even after reprogramming to pluripotency, and it could serve as a key in determining early disease mechanisms in obesity at the level of the CNS. Addition of this platform to the arsenal of currently available obesity disease models may accelerate the development of therapeutics for intervention in patients with morbid obesity.

## RESULTS

### Generation of hiPSC-Derived Hypothalamic Neurons Using Directed Differentiation and Defined Media


Previous studies have reported the generation of hypothalamic-like neurons from human or mouse pluripotent stem cells with varying efficiencies (Merkle et al., 2015; Wang et al., 2015; Wataya et al., 2008) that involve undefined embryoid body differentiation methods and complex serum-based supplements for neuronal specification. Given that neuronal differentiation from hiPSC lines poses a challenge of inter- and intra-cell line variability, we devised a reliable and efficient method for generating iHTNs from hiPSC lines of multiple human donors in a completely chemically defined media without the use of any well-known neuronal supplements like N2 and B27, which consist of  $\sim$ 20 unique chemicals. Thus, we could easily vary concentrations of various components in our cell culture supplement (Table S2) to identify an optimal and reliable iHTN differentiation method that works across multiple hiPSC lines.

The method presented here for the directed generation of iHTNs from hiPSCs involves 3 stages: specification of neural ectoderm, followed by patterning toward ventral diencephalon, and finally maturation of hypothalamic neurons (Figure 1A). The neural ectoderm specification from hiPSCs was achieved by dual SMAD inhibition, followed by Shh activation and Wnt-signaling inhibition via a systematic combinatorial screen, which promoted the greatest percentage of hypothalamic progenitors

based on the observation of NK2 homeobox 1- (Nkx2.1) and homeobox protein orthopedia- (Otp; hypothalamic neuron progenitor that specifies neuropeptidergic neurons) immunopositive cells at day 9 post-hiPSCs (Figures 1B and 1C). Since multiple morphogens, including Wnt, retinoic acid (RA), and insulin (Wataya et al., 2008), are critical in determining hypothalamic identity from hiPSCs, a combinatorial screening in 384-well plates was performed with varying doses of RA, insulin, and IWR-1-endo to efficiently determine the optimal dose for generation of Nkx2.1<sup>hi</sup>, Rax<sup>hi</sup>, and Sox1<sup>lo</sup> neuronal progenitors in this differentiation paradigm between days 2 and 9 of differentiation (Figures 1A, 1D, and 1E; Figures S2B and S2C). Neuronal progenitors of the ventral diencephalon express high levels of Nkx2.1 and Rax (retina and anterior neural fold homeobox, specific to retina and hypothalamus). It was observed that, in hiPSCs seeded in 384-well plates, the absence of insulin was detrimental to cell viability, as the least number of cells were observed in the condition receiving 0  $\mu$ g/mL, while cells treated with 20  $\mu$ g/mL exhibited the largest total cell numbers (Figure S2A). Absence of IWR-1-endo or low concentrations (1  $\mu$ M) resulted in an Nkx2.1<sup>lo</sup> and Sox1<sup>hi</sup> cell population upon screening at day 9 of the protocol. At higher concentrations (10  $\mu$ M) of IWR-1-endo, the largest number of Nkx2.1<sup>hi</sup>, Rax<sup>hi</sup>, and Sox1<sup>lo</sup> cells was observed. While there were higher levels of Rax<sup>hi</sup> cells at 100  $\mu$ M IWR-1-endo, that condition showed low numbers of Nkx2.1<sup>+</sup>, and, furthermore, upon continuation of differentiation, it displayed low cell viability and decreased efficiency of iHTN formation. The absence of RA up to day 9 was also important for obtaining Nkx2.1<sup>hi</sup> and Rax<sup>hi</sup> cell populations. Based on this screening, 0  $\mu$ M RA, 4  $\mu$ g/mL insulin, and 10  $\mu$ M IWR-1-endo was chosen as the most efficient combination for inducing early hypothalamic progenitors from hiPSCs between day 0 and day 9.

### iHTNs Closely Resemble Hypothalamic Neurons of the ARC

After directing the hiPSCs to hypothalamic progenitors, on day 9, the addition of 10 nM RA until day 14 for caudalization and the use of  $\gamma$ -secretase inhibitor DAPT to extend the G1/S phase and thereby exit cell cycle resulted in the largest populations of hypothalamic progenitors and neurons of the ARC. Furthermore, the addition of brain-derived neurotrophic factor (BDNF) until day 40 drove maturation of these neuronal progenitors into neurons that showed markers of hypothalamic ARC, which were capable of secreting neuropeptides. These iHTN progenitors could also be cryopreserved on day 20 of differentiation and reliably thawed (Table S5). Immunocytochemistry characterization of iHTNs obtained from our direct differentiation protocol revealed the presence of hypothalamus- and ARC-specific markers in multiple lines. These included Otp, Rax, NPY (a secreted neuropeptide of the orexigenic NPY neurons), CART (a neuropeptide produced by the anorexigenic CART neurons),  $\alpha$ -MSH (a bioactive product of POMC-producing neurons), NPYR (NPY receptor Y2, receptor for NPY present), GhreR (ghrelin receptor, ghrelin response receptors present in ARC neurons), and MCH (melanin-concentrating hormone, orexigenic hypothalamic peptide found in hypothalamic MCH neurons) (Figure 2B). In addition, indicators of a diverse set of neuropeptidergic neurons that are present in the hypothalamic region were also



**Figure 1. Combinatorial Screening for Forebrain Hypothalamic Neurons**


(A) A schematic of the iHTN direct differentiation protocol.

(B and C) L/SB + SPI combination showing the most (B) Nkx2.1- and (C) Otp-positive progenitor cells. 4 independent experiments utilized 2 different cell lines and an average is represented. Small molecules utilized in (B) and (C) are as follows: L-LDN193189 (1 μM); SB, SB431542 (10 μM); S, Smoothed Agonist (1 μM); P, Purmorphamine (1 μM); I, IWR1-Endo (10 μM); RA, retinoic acid (0.01 μM); BDNF, brain-derived neurotrophic factor (10 ng/mL); C, CHIR99021 (3 μM); R, Rotenone (1 μM); and Cy, Cyclopamine (1 μM).

(D and E) The (D) montage and (E) image (left) and quantification (right) of large-scale combinatorial screen of varying doses of IWR1-endo, insulin, and retinoic acid (RA) in efficient differentiation of (D) Nkx2.1+ hypothalamic progenitors and (E) Rax+ hypothalamic progenitors in day 9 iHTN cultures. The green box in the montage (D) highlights the conditions represented in the bar graphs on the right. Red arrow in (D) denotes the dose combination selected for iHTN differentiation based on efficient Nkx2.1 and long-term neuropeptidergic neuron generation and cell survival. Red arrow in (E) shows that the selected combination shows efficient levels of Rax. 2 independent experiments each utilizing two cell lines were conducted and the average is represented. \*\*\*p < 0.001. Error bars represent SEM.

observed, such as 5HT (serotonin), SST (somatostatin), NP II (neurophysin II), GABA (γ aminobutyric acid), TH (tyrosine hydroxylase), and CPE (carboxypeptidase E) (Figure 2B). The per-

centages of these neuronal subtypes derived from multiple hiPSC lines were scored as a percentage of DAPI+ total cells and quantified at day 40 of differentiation (Figure 2C).



**Figure 2. Characterization of Neuropeptidergic Hypothalamic Neurons**

(A) Schematic of differentiation protocol for iHTNs.

(B) Immunocytochemical staining of iHTNs showing various neuronal, hypothalamic, and neuropeptidergic markers.

(legend continued on next page)

Tracing of the neurites was performed on the immunostained neuropeptidergic neurons to determine neurite length and morphology (Figure 2D). Neuroendocrine neurons expressing SST, 5HT, NP II, and GABA had relatively long neurites compared to neurons expressing ARC-specific markers, such as  $\alpha$ -MSH, CART, CPE, and synaptophysin (SYP) (Figure 2E).

Targeted gene expression revealed that iHTNs expressed typical hypothalamic transcripts, including *Nkx2.1* and ARC-specific genes such as *AgRP*, *NPY*, *MC4R*, and *PCSK2*, in day 40 neurons (Figure 2F). The gene expression results were further supported upon assessing protein levels in the day 40 iHTNs compared to the day 0 hiPSCs by immunoblotting. Day 40 iHTNs showed significantly elevated levels of  $\beta$ -III-tubulin, as well as neuropeptides CART (anorexigenic) and AgRP (orexigenic), relative to their day 0 hiPSC counterparts (Figure 2G). Together, these results suggest that the iHTNs produced by this improved method closely resemble many features of hypothalamic neurons of the ARC.

### Transcriptomic Analysis Confirms Hypothalamic Identity of iHTNs

To determine the fidelity of iHTNs with the adult human hypothalamus, high-coverage (29.5 million reads on average) bulk mRNA sequencing transcriptomic comparisons of multiple day 40 iHTNs and adult post-mortem hypothalamus obtained from UCI Brain Bank (aHT-UCIBB) tissue were performed (Figure S4) (GEO: GSE95243). Spearman correlations were determined for iHTNs and aHT-UCIBB samples in comparison to the reference human hypothalamus gene expression values (transcripts per million [TPM]) obtained from the Genotype-Tissue Expression (GTEx) project (Lonsdale et al., 2013), and they are represented as boxplots (Figure 3A). When compared to all available tissue types in an unsupervised manner, transcriptomes of iHTNs scored similarly to transcriptomes of adult HT tissues. Most importantly, in both iHTNs and aHT-UCIBB tissues, the hypothalamus profile provided by GTEx scored the highest match. Adult HT samples scored 0.72 on average while our iHTN samples scored 0.69. In both cases, the next six closest matching tissues were other forebrain regions of the brain.

The top 500 genes found in the hiPSC-derived HT samples overlapped to a statistically significant degree with five regions of the brain, according to data available from GTEx (Figure 3B). The brain regions indicated included the hypothalamus as well as four regions proximal to the hypothalamus and bearing some functional similarities: hippocampus, putamen, amygdala, and anterior cingulate cortex. A few other tissue types also appeared in the tissue analysis, however, these appeared to be artifacts, as these non-neural tissue hits appeared in the top 500 genes transcribed in both aHT-UCIBB samples we analyzed, as well as the top 500 genes obtained directly from the original GTEx hypothalamus

data (data not shown). The top 500 genes from the iHTNs and aHT-UCIBB tissue and the GTEx data (data not shown) were submitted to the Tissue Specific Expression Analysis (TSEA) tool to enrich for genes associated with the brain. These enriched sets were then submitted to the Cell-Type Specific Expression Analysis (CSEA) tool to be classified against brain regions drawn from BrainSpan: Atlas of the Developing Human Brain (Dougherty et al., 2010; Xu et al., 2014). Using the CSEA, the gene set from the iHTN samples strongly resembled hypocretinergic neurons of the hypothalamus as well as Pnoc+ neurons of the cortex (Figure 3C). Of note, upon CSEA of the human aHT-UCIBB samples, we found that, in addition to the hypocretinergic and Pnoc+ neurons, certain other related cell types were also detected, such as oligodendrocytes and astrocytes from cerebellum and cortex (Figure 3C). Since the aHT-UCIBB samples were obtained from a post-mortem human brain tissue, the glial cells present in the human brain tissue were likely responsible for the presence of non-neuronal cell profiles. However, iHTNs profiled *in vitro* are largely devoid of glial tissue, which explains the absence of oligodendrocyte and astrocyte signatures in the iHTNs.

### iHTNs Exhibit Functional Characteristics and Responsiveness to Exogenous Peptides

We determined whether the iHTNs were electrically active and capable of firing trains of action potentials using Maestro micro-electrode arrays (MEAs) (Figure 4A) in a 48-well-plate format (Axion Biosystems). A raster trace of each of the wells showed measurable firing by the iHTNs for the electrodes in contact with an active neuron (Figure 4B). Each horizontal row represented an electrode in the well. MEA measurements of iHTNs over time exhibited a steady increase in spontaneous electrical activity as the neuronal differentiation time of the culture increased, as indicated by the average spike numbers measured over a period of 10 min (Figure 4C). Average spike numbers for iHTNs steadily increased from day 17 until day 50, suggesting that the iHTNs matured over time and began expressing the complement of ion channels that support trains of spontaneous action potentials.

One of the main functions of ARC hypothalamic neurons is to appropriately respond to hormones and neuropeptides both locally and peripherally. The responsiveness of iHTNs to exogenously added neuropeptides including, ghrelin (orexigenic) and leptin (anorexigenic), was tested by determining whether relevant downstream signaling pathways were activated. Upon the addition of ghrelin, there was an activation of the ghrelin-signaling pathway, measured by an increase in phosphorylation of CREB (pCREB;  $p < 0.001$ ) and phosphorylation of FoxO1 (pFoxO1;  $p < 0.05$ ) (Figure 4D). Upon the addition of leptin, there was an increase in the phosphorylation of Jak2 (pJak2;  $p < 0.05$ ) and STAT3 (pSTAT3;  $p < 0.01$ ), which indicates activation of the

(C) Quantification of the various cell types contained in iHTN cultures ( $n = 8$  lines).


(D) Representative cell traces of iHTNs expressing relevant markers show distinctive morphologies.

(E) Quantification of primary neurite length ( $n = 8$  lines).

(F) qRT-PCR of hypothalamic and arcuate nucleus-specific genes showing significantly increased expression of the genes at day 40 of differentiation compared to day 0 ( $n = 3$  lines).

(G) Representative immunoblots and quantified histograms showing increases in neuron numbers (TUBB3) and arcuate nucleus markers (CART and AgRP) in day 40 cultures compared to day 0 ( $n = 3$  lines). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . All statistical analysis was performed using unpaired t test.

Error bars represent SEM.



(legend on next page)

leptin-induced-signaling pathway (Figure 4D). In concordance with this behavior of iHTNs, ghrelin treatment also increased the release of orexigenic NPY into the culture medium (Figure 4E), while leptin treatment increased anorexigenic  $\alpha$ -MSH release (Figure 4F). These data clearly suggest that the iHTNs were both electrically functional (as measured by their ability to fire spontaneously) and responsive to physiologically relevant neuropeptides necessary for the orexigenic and anorexigenic signaling typical of the hypothalamus. Taken together, these data suggest that this *in vitro*-directed differentiation protocol produces functional iHTNs.

### Super-Obese-Derived iHTNs Show Signatures of Obesity

Disease modeling using hiPSCs has been of tremendous interest in recent years. Whether hiPSCs can model polygenic complex metabolic diseases such as obesity remains to be seen. In this study, we attempted to model obesity by reprogramming hiPSCs derived from five super-obese (OBS) individuals (BMI  $\geq$  50) (Figure 5A) to seven control (CTR) (BMI  $\leq$  25) subjects (Figure S1A) and then comparing the transcriptome signatures of the derived functional iHTNs. Given the severity of the obesity in the OBS donor group, we determined the underlying DNA level genetic variants by performing whole-exome DNA sequencing (WES) (Sequence Read Archive [SRA]: PRJNA416010) and identifying overlap with known obesity-related coding SNPs listed in the phenotype-gene relationships of the Online Mendelian Inheritance in Man (OMIM) obesity database and the Locke study (Locke et al., 2015). Obesity-related SNPs described here were coding variants with high-sequencing coverage (139.5x). All of the 5 OBS donor samples had 3 common variants, 2 on the adrenoceptor beta 2 (*ADRB2*) gene (rs1042714 and rs1042713) and 1 on Bardet-Biedl syndrome 2 (*BBS2*) gene (rs4784677) (Table 1). Four OBS donors shared a common variant in the ectonucleotide pyrophosphatase/phosphodiesterase 1 (*ENPP1*) (rs1044498) and syndecan 3 (*SDC3*) (rs4949184) genes. Additional obesity-related coding variants were observed in leptin receptor (*LEPR*) and peroxisome proliferator-activated receptor gamma (*PPARG*) genes in up to two of the OBS donor hiPSCs.

With respect to iHTN differentiation efficiency, no differences in cell numbers expressing typical hypothalamic markers were observed between the CTR and OBS groups (Figure S3). Differential expression analysis of the bulk mRNA sequencing (mRNA-seq) transcriptome profiles of the two groups revealed dysregulation of relevant genes, which were identified based on a list provided by a combination of GWAS and Metachip datasets meta-analysis of BMI data from 339,224 individuals (Locke et al., 2015). The dysregulated pathways and genes within BMI-associated loci identified by Locke et al. (2015) were enriched for expression in the brain and CNS, including clathrin-coated vesicles, glutamate signaling, and synapse biology.

We identified over half a dozen CNS-specific genes differentially regulated with a p value less than 0.05 in OBS iHTNs that overlapped with the Locke et al. (2015) study (Figure 5B). The relative expression levels of these transcripts were further validated in day 40 iHTNs, and we found that *IRS1* and *TCF7L2* were downregulated in the OBS group, while *NEGR1*, *SCG3*, *SBK1*, *KCTD13*, and *STX1B* were upregulated in the OBS group (Figure 5C) (Locke et al., 2015).

Ingenuity Pathway Analysis performed on all 657 significant differentially expressed genes (DEGs) between CTR and OBS iHTNs revealed that relevant signaling pathways regulating metabolism and energy homeostasis were dysregulated in the OBS group. These included axonal guidance signaling; glutamate receptor signaling; GABA receptor signaling; and G-protein-coupled receptor (GPCR) signaling that includes ghrelin, NPY, and CART receptors, all enriched in the CNS. Further, GPCR-mediated enteroendocrine signaling, endoplasmic reticulum (ER) stress and leptin signaling in obesity, type 2 diabetes mellitus, and adipogenesis were among the metabolic pathways that were perturbed in the OBS iHTNs. Finally, inflammasome, tumor necrosis factor receptor 1 (TNFR1), and high-mobility group box 1 (HMGB1) pathways were significantly enriched for DEGs, and they are known to be associated with obesity-related inflammatory processes in the brain (Figure 5D). To further confirm whether one of these dysregulated pathways manifests at the protein level, we performed immunoblotting on CTR and OBS iHTN lysates, and we evaluated proteins implicated in regulating ER stress specifically (IRE1 $\alpha$ , Ero, and BiP). There was evidence of increased ER stress in OBS iHTNs, as indicated by the increased expression of IRE1 $\alpha$  (ER transmembrane stress sensor protein) and decreased expression of proteins controlling folding, Ero and BiP (Figure 5E). Taken together, the WES and transcriptomic profiling of iHTNs point toward the possibility that the obesity-associated coding variants may contribute to these disease signatures even after reprogramming somatic cells.

### OBS-Derived iHTNs Have Perturbations in Metabolism and Responses to Exogenous Neuropeptides


Next, the effect of obesity on iHTN mitochondrial respiratory function was determined by performing a mitochondrial stress test with the XF<sup>24</sup> Seahorse Extracellular Flux Analyzer. Interestingly, the oxygen consumption rate of iHTNs in the OBS group was significantly lower than the CTR group, pointing toward a decrease in basal mitochondrial respiration and oxygen consumption rate (OCR) in OBS iHTNs (Figure 6A). Additionally, the OBS iHTNs were more glycolytic than CTR iHTNs, as measured by a plot of the extracellular acidification rate (ECAR) versus OCR (Figure 6B). No differences were observed in the respiration rates in the iHTNs upon ghrelin or leptin addition compared to untreated condition (Figure S5).

### Figure 3. Characterization of Tissue and Cell Specificity of iHTNs

(A) A boxplot showing Spearman correlations in iHTNs (n = 12) and post-mortem adult HT tissue (aHT[UCIBB]) (n = 6) compared to GTEx hypothalamus (aHT [GTEx]) gene expression.

(B) Tissue Specific Expression Analysis (TSEA) of iHTNs (left) and aHT(UCIBB) (right) using GTEx, showing that lab-generated iHTNs are brain related in origin (green boundary) and express forebrain- and hypothalamus-specific genes similar to adult hypothalamus tissue.

(C) Cell-Type Specific Expression Analysis (CSEA) of iHTNs (left) and aHT (right) using BrainAtlas, showing that lab-generated iHTNs comprise predominantly hypothalamic neurons in culture.



**Figure 4. iHTNs Exhibit Electrical Activity and Response to Exogenous Peptides**

(A) An image of a 48-well microelectrode array (MEA) plate used for measuring neuronal electrophysiological activity over a 30-day period during iHTN differentiation and maturation.

(B) A representative raster trace of iHTNs in a well measured on day 52. Each horizontal row represents an electrode in the well.


(C) Plot representing average neuronal spike number in the iHTNs measured from day 15 to day 50 of iHTN development (n = 6 lines in 3 × 48 wells with each line seeded in 24 wells of a plate).

(D) Representative immunoblots and densitometry quantification in histograms showing signaling response of iHTNs to either untreated (Unt) control or exposed to exogenous ghrelin (left) and leptin (right). Activation of the respective pathway proteins is demonstrated via pCREB and pFoxo1 for ghrelin signaling and pSTAT3 and pJak2 for leptin signaling.

(E and F) ELISA measurements showing increased NPY secretion with ghrelin treatment (E) and increased  $\alpha$ -MSH secretion with leptin treatment (F). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001. Data shown are representative of results from differentiated iHTNs in n = 3 independent experiments. Error bars represent SEM.

To investigate whether CTR or OBS iHTNs respond to hormonal signals similarly, the iHTNs derived from multiple hiPSC lines were exposed to ghrelin and leptin neuropeptides, and their differential responses were examined by measuring

downstream signaling responses. Upon exposure to ghrelin, as described previously, the CTR iHTNs appropriately exhibited an increase in phosphorylation of CREB (pCREB) and Foxo1 (pFoxo1). The OBS iHTNs responded similarly, by increasing



**Figure 5. Transcriptome Profiling of iHTNs from Super-Obese Patients Displays Molecular Signatures of Metabolic Disease and Obesity**

(A) Patient information on super-obese (OBS) patient-derived hiPSC lines.  
 (B) Scatterplot highlighting dysregulated expression of genes in iHTNs derived from normal control (BMI < 25) versus OBS patients (BMI > 25) based on RNA sequencing data and correlated with obesity-related gene identified in Locke et al. (2015) (n = 12 lines).  
 (C) qRT-PCR validation of genes identified from Locke et al. (2015) showing increased expression of *NEGR1*, *ELAVL1*, *SCG3*, *STXB1*, *SBK1*, and *KCTD13* and decreased expression of *IRS1* and *TCF7LS* in the OBS group compared to CTR (n = 10 lines).  
 (D) Ingenuity Pathway Analysis showing differentially regulated pathways. Size of each node represents the p value, while the thickness of lines connecting each node represents the number of common genes shared between the two pathways (n = 12 lines).  
 (E) Immunoblot validation of endoplasmic reticulum (ER) stress pathway, where OBS iHTNs confirm ER stress activation with an increase in IRE1 $\alpha$  and a decrease in Ero and BiP compared to CTR (n = 3 independent experiments consisting of one CTR and one OBS line each). \*p < 0.05, \*\*\*p < 0.001. Error bars represent SEM.

pCREB and pFoxO1 levels upon ghrelin exposure; however, the OBS iHTNs' response was stronger relative to the levels of pCREB and pFoxO1 in ghrelin-treated CTR iHTNs. This increased signaling response to an orexigenic hormone such

as ghrelin suggests that OBS iHTNs retained an innate increased food intake-signaling response in the presence of ghrelin (Figure 6C). Conversely, baseline leptin signaling (i.e., absent exogenous leptin treatment) was higher in OBS iHTNs relative to CTR

**Table 1. Coding SNPs Found in Exome-Sequenced Obesity hiPSC Lines**

Gene	SNP ID	Chromosome	Position	Base Change	Amino Acid Change	Alternative Base Frequency	Lines Containing	Homozygous  Heterozygous	OMIM
ADRB2	rs1042714	5	148,206,473	G > C	Glu > Gln	0.796	5	5   0	601665
	rs1042713	5	148,206,440	G > A	Gly > Arg	0.476	5	2   3	601665
ENPP1	rs1044498	6	132,172,368	A > C	Lys > Gln	0.342	4	2   2	601665/ 125853
LEPR	rs1137101	1	66,058,513	A > G	Gln > Arg	0.584	2	1   1	614963
	rs1805094	1	66,075,952	G > C	Lys > Asn	0.142	2	0   2	614963
	rs1137100	1	66,036,441	A > G	Lys > Arg	0.320	1	0   1	614963
PPARG	rs3856806	3	12,475,557	C > T	His	0.127	2	0   2	604367/ 125853
SDC3	rs2282440	1	31,347,320	G > A	Asp > Asn	0.161	1	1   2	601665
	rs4949184	1	31,347,399	C > T	Val > Ile	0.234	4	1   3	601665
	rs2491132	1	31,349,647	C > T	Thr > Ile	0.076	1	0   1	601665
BBS2	rs4784677	16	56,548,501	C > T	Ser > Asn	0.996	5	5   0	615981

The exome of each obese cell line was compared to the OMIM database of SNPs associated with obesity and with a list of potentially relevant SNPs described in [Locke et al. \(2015\)](#). SNPs from genes of relevance are shown above. Chromosome and position indicate the chromosome and locus of the SNP. Base change and amino acid change indicate the typical and alternative nucleotide and the resulting amino acid change during protein translation. Alternative base frequency is the frequency at which the mutation is observed in the world population. The lines containing column lists the number of lines in which the SNP was found and the zygosity column lists the number of lines in which the SNP was found on both chromosomes or on a single chromosome. The OMIM column contains a SNP entry in the Online Mendelian Inheritance in Man (OMIM) database.

iHTNs based on increased levels of pJak2 and STAT3 (pSTAT3). Upon exogenous leptin treatment, CTR iHTNs showed significantly increased pJak2 and pSTAT3, while OBS iHTNs only showed a significant increase in pJak2, but not in pSTAT3 ([Figure 6D](#)). These data suggest elevated baseline activation of the leptin-signaling pathway in the OBS iHTNs in the absence of exogenous signaling molecules.


With regard to neuropeptide secretion, orexigenic NPY was measured in the cell culture media following ghrelin treatment of iHTNs, and both CTR iHTNs and OBS iHTNs responded to ghrelin by secreting increased levels of NPY ([Figure 6E](#)). Although both groups responded to ghrelin treatment, it is noteworthy that OBS iHTNs again showed an exacerbated response to ghrelin treatment by secreting higher levels of NPY compared to CTR iHTNs. On the other hand, when leptin treatment was performed and secretion levels of anorexigenic  $\alpha$ -MSH were assessed, we found that both iHTNs from CTR and OBS showed increased secretion of  $\alpha$ -MSH at similar magnitudes ([Figure 6F](#)).

## DISCUSSION

hiPSCs offer great promise in the field of disease modeling. Several neurodevelopmental ([Chamberlain et al., 2010](#); [Fuller et al., 2016](#); [Sareen et al., 2012](#)), neurodegenerative ([Israel et al., 2012](#); [Reinhardt et al., 2013](#); [Yagi et al., 2011](#)), and metabolic diseases ([Gu et al., 2015](#); [Wang et al., 2015](#)) have been successfully modeled using hiPSCs. Given the seriousness of the global obesity epidemic and the alarming rise in the rate of childhood obesity, this study focused on determining whether we can successfully model aspects of CNS involvement in non-monogenic forms of obesity, which may have complex etiological origins. This study describes a reliable, controlled, efficient, and reproducible protocol for the genera-

tion of hypothalamic, neuropeptidergic neurons capable of secreting neurohormones, and it demonstrates that these neurons are responsive to exogenous hormone signals. The ultimate goal was to determine whether hypothalamic neuropeptidergic neurons derived from reprogrammed patient hiPSCs could faithfully capture signatures of complex obesity, by comparing differentiated hypothalamic neurons from hiPSCs of multiple normal BMI and OBS individuals with known coding variants in obesity loci. We observed that certain molecular and pathway-level signatures of human obesity can be recapitulated by diseased iHTNs derived from OBS patients, despite undergoing reprogramming and re-differentiation to hypothalamic neuronal cells. This study thus widens the application of hiPSCs in modeling CNS involvement in obesity as well as other metabolic diseases.

Differentiation of hypothalamic neuropeptidergic neurons has been previously described using mouse embryonic stem cells (ESCs) ([Wataya et al., 2008](#)), human ESCs ([Merkle et al., 2015](#)), and hiPSCs ([Wang et al., 2015](#)). Although these studies describe the generation of hypothalamic neurons at low differentiation efficiencies from a handful of PSC lines, in the context of metabolic diseases, it becomes necessary to verify the responsiveness of the *in vitro*-derived neuroendocrine neurons to various hormonal signals in order for them to be utilized as a valid model of metabolic signaling defects and testing strategies for therapeutic intervention. In this regard, we successfully demonstrated differentiation of multiple hiPSC lines from over 10 donors. Our results show that iHTN cultures are a mixed population of both orexigenic AgRP/ NPY and anorexigenic POMC/CART neurons; hence, we rightly believed that they would respond well to both orexigenic (ghrelin) and anorexigenic (leptin) signals, and transcriptional profiles showed the highest correlation with the RNA isolated from human brain hypothalamus.



**Figure 6. Functional Comparison of Control and OBS-Derived iHTNs**

(A) Seahorse mitochondrial respirometry histogram showing decreased OCR in OBS iHTNs compared to control (CTR) iHTNs.

(B) Comparison of OCR versus extracellular acidification rate (ECAR, glycolysis measure) showing higher ECAR and lower OCR in OBS iHTNs. LE, less energetic; MA, more aerobic; MG, more glycolytic; ME, more energetic.

(C and D) Representative immunoblots showing activation of ghrelin pathway upon ghrelin treatment in iHTNs as measured by phosphorylation of CREB and FoxO1 (C) and moderate or no activation of leptin pathway upon leptin treatment as measured by phosphorylation of Jak2 and STAT3 (D).

(E) NPY secretion measured by ELISA showing increased response of OBS iHTNs to ghrelin exposure.

(F)  $\alpha$ -MSH secretion measured by ELISA comparing baseline (Unt) to leptin treatment. Both CTR and OBS iHTNs were responsive to leptin exposure and increased  $\alpha$ -MSH secretion; however, this measure was not significantly different between CTR and OBS groups. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Data shown are representative of results from differentiated iHTNs used in  $n = 3$  independent experiments consisting of one CTR and one OBS line each.


Error bars represent SEM.

In addition to the iHTN transcriptome profiles supporting the efficacy of our model to produce physiologically relevant hypothalamic neurons, this RNA-seq data also support the role of genetic loci that have been associated with obesity biology based on BMI (Locke et al., 2015). Specifically, several genetic loci for increased BMI were also differentially expressed in OBS iHTNs compared to CTR iHTNs. *NEGR1* expression was increased in OBS, and this gene has been associated with synaptic function, glutamate signaling, and, most interestingly, extreme/early onset obesity. We also found *TCF7L2* decreased in OBS compared to controls. *TCF7L2* encodes a transcription factor of the same name, which has been implicated in type 2 diabetes (Jin and Liu, 2008), especially proglucagon (blood glucose-elevating pro-hormone) synthesis whereby activation of *TCF7L2* leads to the repression of proglucagon synthesis. We found that *TCF7L2* is lower in OBS individuals thereby possibly causing an increase in the production of proglucagon and risk of developing diabetes (Grant et al., 2006). *IRS1* was also found to be downregulated in OBS, suggesting the dysregulation of yet another gene involved in the pathogenesis of type 2 diabetes (Kovacs et al., 2003). Among the other genes differentially regulated were *KCTD13*, a gene associated with sweet taste signaling, which is known to be a glucose sensor in hypothalamus (Ren et al., 2009), and

that are differentially regulated in the OBS-derived iHTNs suggest there is a strong tendency toward dysregulation of endocrine and metabolic processes known to be abnormal in obese individuals.

Furthermore, pathway analysis of these DEGs between OBS iHTNs and CTR iHTNs revealed several dysregulated pathways relevant in obesity. For example, we found dysregulation of several endocrine-signaling pathways such as leptin signaling in obesity and cholecystokinin/Gastrin-mediated signaling, pointing toward a skewed response to these critical endocrine hormones, which are hallmarks of obesity (Chen et al., 2016; Lee et al., 2001). Additionally, many of the receptor-signaling pathways were also dysregulated, such as GPCR, GPCR-mediated enteroendocrine signaling, as well as glutamate receptor, GABA receptor, and serotonin receptor (also GPCRs) pathways, all of which are strongly involved in the neurotransmission and neuronal signaling.

The OBS donors contain polygenic obesity-related SNPs, suggesting these coding variants likely contribute to the obese phenotype exhibited by the iHTNs. The main SNPs were observed in obesity-related genes coding for *LEPR*, *SDC3*, *ADRB2*, *ENPP1*, *PPARG*, and *BBS2*. All 5 of the OBS hiPSCs contained SNPs in three regions: two variants of *ADRB2* and



**Figure 7. A Schematic Representation of the Hormonal Responses in CTR and OBS iHTNs in Baseline and Hormone-Treated Conditions**

(A) At baseline, CTR iHTNs (left) show baseline levels of orexigenic (pCREB and pFoxO1) and anorexigenic pathway proteins (Jak2 and STAT3) and a baseline response to added hormones to maintain a balance between food intake (NPY) and energy expenditure ( $\alpha$ -MSH). At baseline, OBS iHTNs (right) show an imbalance in food intake versus energy expenditure in that there is an activation of the orexigenic pathway while the anorexigenic pathway is not equally active.

(B) Upon treatment of relevant hormones such as ghrelin (orexigenic) and leptin (anorexigenic), the CTR iHTNs (left) maintain their balance between food intake and energy expenditure. Interestingly, OBS iHTNs (right) show a further imbalance in that there is a further increase in orexigenic signals upon ghrelin treatment, but leptin does not elicit an equally effective anorexigenic response. As a result, OBS iHTNs show exacerbated orexigenic signals as well as possible resistance to leptin.

one variant on the *BBS2* gene. Both variants of the *ADRB2* gene (rs1042713 and rs1042714) have been shown to be associated with obesity and/or BMI (Gjesing et al., 2007, 2009; Hayakawa et al., 2000). Although some studies did not find an association of these SNPs with obesity (Bengtsson et al., 2001; Pereira et al., 2003), the rs1042714-related 27Glu allele was shown to be significantly associated with obesity in Asians, Pacific Islanders, and Native Americans (Jalba et al., 2008). The *BBS2* variant rs4784677 has also been associated with obesity (<http://omim.org/entry/606151>). This is a rare SNP for Bardet-Biedl Syndrome (BBS) and includes obesity as one of its clinical features. BBS in itself is a complex trait needing three mutant alleles for manifesting the phenotype. Hence, associating obesity with a mutation in the *BBS2* gene cannot be done with confidence.

Besides these genes, SNPs in other obesity-related genes were observed in one or more of the obesity donors, but not in all. Several obesity-related SNPs in *LEPR* genes, such as rs1137101 (Furusawa et al., 2010), rs1805094 (Rojano-Rodriguez et al., 2016), and rs1137100 (Hastuti et al., 2016), were observed. *PPARG* SNP rs3856806 was observed in two samples, which have been associated with risk of obesity and type 2 diabetes (Lv et al., 2017). Two other obesity samples showed SNPs in one locus each for *SDC3* gene, rs2491132 and rs2282440, both of which have been associated with obesity (Ha et al., 2006). Besides the above SNPs, four of our samples showed polymorphism in the *ENPP1* gene (rs1044498), although some studies have failed to show a consistent association of this

SNP with obesity (Grarup et al., 2006; Lyon et al., 2006; Zhao et al., 2011). We believe that the mutations found in the severe obesity donors used in this study provide a compelling explanation for the retained obesity phenotype exhibited by OBS hiPSC-derived iHTNs. Energy metabolism differed between the iHTNs from control versus OBS patients, consistent with the critical role of mitochondrial metabolism in ghrelin's effects on NPY/AgRP neurons (Andrews et al., 2008). Future studies will explore the changes to mitochondrial metabolism in response to ghrelin between CTR and OBS iHTNs, particularly to examine UCP2 and free radical production, which are important to this pathway (Andrews et al., 2008, 2009; Toda and Diano, 2014).

Studies have shown the presence of increased levels of ghrelin in obesity (Cummings et al., 2002), but not much information is available on the effect of elevated ghrelin at a molecular level. We show that similar amounts of exogenously added ghrelin elicit an exaggerated effect in OBS iHTNs compared to CTR iHTNs. Thus, increased ghrelin levels in obese individuals, combined with hyper-responsive neurons, might result in exacerbated orexigenic signaling.

While baseline levels of CREB and FoxO1 were not different between CTR and OBS iHTNs, we found a significant increase in the baseline levels of pJAK2 and pSTAT3 levels between the two groups, suggesting that at baseline there could be an increase in leptin levels, which is a hallmark of obesity (Scarpace and Zhang, 2007). In response to exogenous leptin, however, pJAK2 and  $\alpha$ -MSH secretion levels increased, but pSTAT3 did not. Unlike exogenous ghrelin exposure, OBS iHTNs did not show any exacerbated leptin-signaling response upon leptin exposure (Figure 7). These data suggest that OBS iHTNs have increased baseline leptin levels as well as a non-dramatic leptin signaling upon exposure to exogenous leptin, pointing toward a

possible leptin resistance, which is also typical of obesity (Knight et al., 2010).

In this study, the use of hiPSCs served as a unique platform for modeling obesity. The possibility to elucidate developmental and metabolic cues into the cause of obesity retrospectively has been made possible by this platform. Obtaining metabolically relevant tissues or cell types such as the hypothalamic neurons of the ARC from living individuals struggling with obesity would otherwise be impossible. hiPSC-based models offer great promise in dissecting the role of individual cell types in the onset of the disease, and they provide a platform of living cells that can be used for high-throughput drug screening. It is thus evident that polygenic obesity can be modeled using differentiated neurons derived from hiPSCs of donors afflicted with severe obesity. Although the patient lines had polygenic SNPs at few obesity loci, gene expression and molecular and metabolic profiling of the hypothalamic neurons revealed convergence of these DNA-level variants on specific obesogenic phenotypes *in vitro*. While this study particularly focused on obesity, there are several other disorders associated with hypothalamic dysfunction that could potentially be modeled and evaluated with this iHTN differentiation method, such as anorexia nervosa, alcoholism, diabetes mellitus and insipidus, anxiety disorders, as well as certain rare diseases hallmarked by neuroendocrine abnormalities. Likewise, many approved drugs used to treat patients with mental illness, such as antidepressants, antipsychotics, and mood stabilizers, can cause metabolic syndrome in some patients and ultimately lead to physical diseases of obesity, diabetes, and cardiovascular disease (Correll et al., 2015). Such patient-derived iHTN models may provide a platform to evaluate the mechanisms behind these unwanted side effects, and they could potentially be used to identify which patients are more susceptible to these unwanted outcomes.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - iPSC Model
  - Adult Post-Mortem Brain Sections
  - Subject Details
- **METHOD DETAILS**
  - Ethics Statement and Reprogramming to iPSCs
  - iPSC-derived hypothalamic neuron differentiation (iHTN)
  - Adult hypothalamic tissue (aHT-UCIBB) processing
  - Immunofluorescence
  - Quantitative PCR
  - Immunoblots
  - RNA sequencing
  - $\alpha$ -MSH ELISA
  - NPY ELISA
  - Metabolic Phenotyping and Seahorse Respirometry Assay

- MEA measurements
- Exogenous peptide treatments
- Whole Exome Sequencing: Library preparation and sequencing
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Neuron tracing and neurite length measurement
  - Data analysis for RNA seq
  - Identification and analysis of Single Nucleotide Variants
  - Statistical Analysis of Protein Expression
- **DATA AND SOFTWARE AVAILABILITY**

## SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and six tables and can be found with this article online at <https://doi.org/10.1016/j.stem.2018.03.009>.

## ACKNOWLEDGMENTS

We would like to acknowledge Rebecca Hernandez for her contribution in conducting part of the hormone treatment experiments, ELISA, and immunocytochemistry (ICC). We would also like to acknowledge the donors that provided biospecimens tissue (blood, LCLs, and fibroblasts) for hiPSC generation, as well as the autopsy donors and their families for providing tissue to the UCI Brain Bank, without whom these studies would not have been possible. This work was supported by Cedars-Sinai institutional programmatic funds (D.S.) and in part by the NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI grant UL1TR000124. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## AUTHOR CONTRIBUTIONS

U.R. performed all differentiations and characterizations of iHTNs, mRNA isolation for RNA sequencing and qPCR, all exogenous hormone experiments, respirometry experiments, and data analysis. A.R.G. performed transcriptome and whole-exome DNA sequencing bioinformatics analyses and contributed to drafting the manuscript. B.E.H. coordinated collection of the adult post-mortem hypothalamus tissue from the UCI Brain Bank (UCIBB), extracted RNA, performed RNA integrity analysis, evaluated RNA-seq data for mRNA read quantity and quality prior to bioinformatics analysis, and edited/reviewed the manuscript. A.S. performed regional identification of hypothalamic tissue in post-mortem brains, supervised hypothalamus tissue microdissections, and reviewed the manuscript. M.P.V. evaluated the UCIBB database for available and high-quality post-mortem hypothalamus tissue, coordinated arrangement for tissue to be provided to Cedars-Sinai for these studies, and reviewed the manuscript. A.M.A. helped with design, optimization, and analysis of Seahorse respirometry. R.A.G. helped in the design and analysis of respirometry data and review of the manuscript. J.T., V.G., and Y.W. conducted and performed the bulk mRNA-seq and whole-exome DNA sequencing experiments as well as bioinformatics analysis. D.S. conceptualized the study design, analyzed data, wrote the manuscript, supported with funding, and developed the differentiation protocol and experimental planning.

## DECLARATION OF INTERESTS

A provisional patent application 62/354,04 describing methods and compositions for differentiation of iPSCs has been filed in the United States Patent and Trademark Office. Apart from the patent filing, the authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: July 17, 2017  
 Revised: February 6, 2018  
 Accepted: March 12, 2018  
 Published: April 19, 2018

## REFERENCES

- Andrews, Z.B., Liu, Z.W., Wallingford, N., Erion, D.M., Borok, E., Friedman, J.M., Tschöp, M.H., Shanabrough, M., Cline, G., Shulman, G.I., et al. (2008). UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. *Nature* 454, 846–851.
- Andrews, Z.B., Erion, D., Beiler, R., Liu, Z.-W., Abizaid, A., Zigman, J., Elsworth, J.D., Savitt, J.M., DiMarchi, R., Tschoep, M., et al. (2009). Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. *J. Neurosci.* 29, 14057–14065.
- Barrett, R., Ormelas, L., Yeager, N., Mandefro, B., Sahabian, A., Lenaeus, L., Targan, S.R., Svendsen, C.N., and Sareen, D. (2014). Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines. *Stem Cells Transl. Med.* 3, 1429–1434.
- Bengtsson, K., Orho-Melander, M., Melander, O., Lindblad, U., Ranstam, J., Råstam, L., and Groop, L. (2001). Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. *Hypertension* 37, 1303–1308.
- Bragina, O., Sergejeva, S., Serg, M., Zarkovsky, T., Maloverjan, A., Kogerman, P., and Zarkovsky, A. (2010). Smoothed agonist augments proliferation and survival of neural cells. *Neurosci. Lett.* 482, 81–85.
- Chamberlain, S.J., Chen, P.-F., Ng, K.Y., Bourgois-Rocha, F., Lemtiri-Chlieh, F., Levine, E.S., and Lalonde, M. (2010). Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. *Proc. Natl. Acad. Sci. USA* 107, 17668–17673.
- Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* 27, 275–280.
- Chen, J., Chen, L., Sanseau, P., Freudenberg, J.M., and Rajpal, D.K. (2016). Significant obesity-associated gene expression changes occur in the stomach but not intestines in obese mice. *Physiol. Rep.* 4, e12793.
- Correll, C.U., Detraux, J., De Lepeleire, J., and De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry* 14, 119–136.
- Cummings, D.E., Clement, K., Purnell, J.Q., Vaisse, C., Foster, K.E., Frayo, R.S., Schwartz, M.W., Basdevant, A., and Weigle, D.S. (2002). Elevated plasma ghrelin levels in Prader Willi syndrome. *Nat. Med.* 8, 643–644.
- DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* 43, 491–498.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dougherty, J.D., Schmidt, E.F., Nakajima, M., and Heintz, N. (2010). Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. *Nucleic Acids Res.* 38, 4218–4230.
- Fuller, H.R., Mandefro, B., Shirran, S.L., Gross, A.R., Kaus, A.S., Botting, C.H., Morris, G.E., and Sareen, D. (2016). Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development. *Front. Cell. Neurosci.* 9, 506.
- Furusawa, T., Naka, I., Yamauchi, T., Natsuhara, K., Kimura, R., Nakazawa, M., Ishida, T., Inaoka, T., Matsumura, Y., Ataka, Y., et al. (2010). The Q223R polymorphism in LEPR is associated with obesity in Pacific Islanders. *Hum. Genet.* 127, 287–294.
- Gjesing, A.P., Andersen, G., Burgdorf, K.S., Borch-Johnsen, K., Jørgensen, T., Hansen, T., and Pedersen, O. (2007). Studies of the associations between functional  $\beta$ 2-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects. *Diabetologia* 50, 563–568.
- Gjesing, A.P., Sparso, T., Borch-Johnsen, K., Jørgensen, T., Pedersen, O., Hansen, T., and Olsen, N.V. (2009). No consistent effect of ADRB2 haplotypes on obesity, hypertension and quantitative traits of body fatness and blood pressure among 6,514 adult Danes. *PLoS ONE* 4, e7206.
- Grant, S.F.A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadóttir, A., et al. (2006). Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat. Genet.* 38, 320–323.
- Grarup, N., Urhammer, S.A., Ek, J., Albrechtsen, A., Glümer, C., Borch-Johnsen, K., Jørgensen, T., Hansen, T., and Pedersen, O. (2006). Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. *Diabetologia* 49, 2097–2104.
- Gu, M., Mordwink, N.M., Kooreman, N.G., Lee, J., Wu, H., Hu, S., Churko, J.M., Diecke, S., Burrige, P.W., He, C., et al. (2015). Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. *Eur. Heart J.* 36, 806–816.
- Ha, E., Kim, M.-J., Choi, B.-K., Rho, J.-J., Oh, D.-J., Rho, T.-H., Kim, K.-H., Lee, H.J., Shin, D.-H., Yim, S.V., et al. (2006). Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the Korean population. *J. Clin. Endocrinol. Metab.* 91, 5095–5099.
- Hamosh, A., Scott, A.F., Amberger, J., Bocchini, C., Valle, D., and McKusick, V.A. (2002). Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res.* 30, 52–55.
- Hastuti, P., Zukhrufia, I., Padwaswari, M.H., Nuraini, A., and Sadewa, A.H. (2016). Polymorphism in leptin receptor gene was associated with obesity in Yogyakarta, Indonesia. *Egypt. J. Med. Hum. Genet.* 17, 271–276.
- Hayakawa, T., Nagai, Y., Kahara, T., Yamashita, H., Takamura, T., Abe, T., Nomura, G., and Kobayashi, K. (2000). Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene are not associated with obesity in Japanese men. *Metabolism* 49, 1215–1218.
- Hendricks, A.E., Bochukova, E.G., Marenne, G., Keogh, J.M., Atanassova, N., Bounds, R., Wheeler, E., Mistry, V., Henning, E., Körner, A., et al.; Understanding Society Scientific Group; EPIC-CVD Consortium; UK10K Consortium (2017). Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity. *Sci. Rep.* 7, 4394.
- Hu, Y., Qu, Z.Y., Cao, S.Y., Li, Q., Ma, L., Krencic, R., Xu, M., and Liu, Y. (2016). Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. *J. Neurosci. Methods* 266, 42–49.
- Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S., et al. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 482, 216–220.
- Jalba, M.S., Rhoads, G.G., and Demissie, K. (2008). Association of codon 16 and codon 27 beta 2-adrenergic receptor gene polymorphisms with obesity: a meta-analysis. *Obesity (Silver Spring)* 16, 2096–2106.
- Jin, T., and Liu, L. (2008). The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. *Mol. Endocrinol.* 22, 2383–2392.
- Knight, Z.A., Hannan, K.S., Greenberg, M.L., and Friedman, J.M. (2010). Hyperleptinemia is required for the development of leptin resistance. *PLoS ONE* 5, e11376.
- Kovacs, P., Hanson, R.L., Lee, Y.-H., Yang, X., Kobes, S., Permana, P.A., Bogardus, C., and Baier, L.J. (2003). The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. *Diabetes* 52, 3005–3009.
- Lee, J.H., Reed, D.R., and Price, R.A. (2001). Leptin resistance is associated with extreme obesity and aggregates in families. *Int. J. Obes. Relat. Metab. Disord.* 25, 1471–1473.
- Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 12, 323.
- Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., et al.; LifeLines Cohort Study; ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium (2015).

- Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518, 197–206.
- Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al.; GTEx Consortium (2013). The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* 45, 580–585.
- Lv, X., Zhang, L., Sun, J., Cai, Z., Gu, Q., Zhang, R., and Shan, A. (2017). Interaction between peroxisome proliferator-activated receptor gamma polymorphism and obesity on type 2 diabetes in a Chinese Han population. *Diabetol. Metab. Syndr.* 9, 7.
- Lyon, H.N., Florez, J.C., Bersaglieri, T., Saxena, R., Winckler, W., Almgren, P., Lindblad, U., Tuomi, T., Gaudet, D., Zhu, X., et al. (2006). Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity. *Diabetes* 55, 3180–3184.
- MacLean, P.D. (1968). The human brain in figures and tables: A quantitative handbook, by S. M. Blinkov and I. I. Glezer. *Science* 161, 454–455.
- Merkle, F.T., Maroof, A., Wataya, T., Sasai, Y., Studer, L., Eggen, K., and Schier, A.F. (2015). Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells. *Development* 142, 633–643.
- Pereira, A.C., Floriano, M.S., Mota, G.F.A., Cunha, R.S., Herkenhoff, F.L., Mill, J.G., and Krieger, J.E. (2003). Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. *Hypertension* 42, 685–692.
- Reinhardt, P., Schmid, B., Burbulla, L.F., Schöndorf, D.C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, S.A., Dhingra, A., et al. (2013). Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. *Cell Stem Cell* 12, 354–367.
- Ren, X., Zhou, L., Terwilliger, R., Newton, S.S., and de Araujo, I.E. (2009). Sweet taste signaling functions as a hypothalamic glucose sensor. *Front. Integr. Neurosci.* 3, 12.
- Rojano-Rodriguez, M.E., Beristain-Hernandez, J.L., Zavaleta-Villa, B., Maravilla, P., Romero-Valdovinos, M., and Olivo-Diaz, A. (2016). Leptin receptor gene polymorphisms and morbid obesity in Mexican patients. *Hereditas* 153, 2.
- Rong, Y.P., Liu, F., Zeng, L.C., Ma, W.J., Wei, D.Z., and Han, Z.G. (2002). Cloning and characterization of a novel human secretory protein: secretogranin III. *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)* 34, 411–417.
- Sareen, D., Ebert, A.D., Heins, B.M., McGivern, J.V., Ornelas, L., and Svendsen, C.N. (2012). Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. *PLoS ONE* 7, e39113.
- Scarpace, P.J., and Zhang, Y. (2007). Elevated leptin: consequence or cause of obesity? *Front. Biosci.* 12, 3531–3544.
- Toda, C., and Diano, S. (2014). Mitochondrial UCP2 in the central regulation of metabolism. *Best Pract. Res. Clin. Endocrinol. Metab.* 28, 757–764.
- Utiger, R. (2017). Hypothalamus (Encycl. Britannica, Inc.).
- Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164.
- Wang, L., Meece, K., Williams, D.J., Lo, K.A., Zimmer, M., Heinrich, G., Martin Carli, J., Leduc, C.A., Sun, L., Zeltser, L.M., et al. (2015). Differentiation of hypothalamic-like neurons from human pluripotent stem cells. *J. Clin. Invest.* 125, 796–808.
- Wataya, T., Ando, S., Muguruma, K., Ikeda, H., Watanabe, K., Eiraku, M., Kawada, M., Takahashi, J., Hashimoto, N., and Sasai, Y. (2008). Minimization of exogenous signals in ES cell culture induces rostral hypothalamic differentiation. *Proc. Natl. Acad. Sci. USA* 105, 11796–11801.
- Xu, X., Wells, A.B., O'Brien, D.R., Nehorai, A., and Dougherty, J.D. (2014). Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders. *J. Neurosci.* 34, 1420–1431.
- Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., and Suzuki, N. (2011). Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum. Mol. Genet.* 20, 4530–4539.
- Zhao, T., Liu, Z., Zhang, D., Liu, Y., Yang, Y., Zhou, D., Chen, Z., Yu, L., Zhang, Z., Feng, G., et al. (2011). The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population. *J. Hum. Genet.* 56, 12–16.

## STAR★METHODS

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Nkx2.1	EMD Millipore	Cat# MAB5460 RRID: AB_571072
OTP	GeneTex	Cat# GTX119601 RRID: AB_11164017
SOX1	R&D Systems	Cat# AF3369 RRID: AB_2239879
Rax	ThermoFisher Scientific	Cat# PA5-11477 RRID: AB_2284916
NPY	Millipore	Cat# AB9608 RRID: AB_2153720
CART	Santa Cruz	Cat# sc-18068 RRID: AB_2068572
$\alpha$ -MSH	Phoenix Pharmaceuticals	Cat# H-043-01 RRID: AB_10013604
NPYR	Alomone Labs	Cat# ANR022 RRID: AB_2040032
GhrR	Alomone Labs	Cat# AGR031 RRID: AB_2340976
MCH	Sigma Aldrich	Cat# M8440 RRID: AB_260690
Serotonin	Immunostar	Cat# 20080 RRID: AB_572263
Somatostatin	Santa Cruz	Cat# sc-13099 RRID: AB_2195930
Neurophysin II	Santa Cruz	Cat# sc-27093 RRID: AB_2061964
GABA	Sigma-Aldrich	Cat# A2052 RRID: AB_477652
Tyrosine Hydroxylase	Immunostar	Cat# 22941 RRID: AB_572268
Carboxypeptidase E	R&D Systems	Cat# AF3587 RRID: AB_2083766
$\beta$ III Tubulin	Sigma-Aldrich	Cat# T8660 RRID: AB_477590
COX IV	Cell Signaling Technology	Cat# 4850 RRID: AB_2085424
pCREB	Cell Signaling Technology	Cat# 9198S RRID: AB_2561044
CREB Total	Cell Signaling technology	Cat# 9197S RRID: AB_331277
pFOXO1	Cell Signaling technology	Cat# 9461S RRID: AB_329831
FOXO1 Total	Cell Signaling Technology	Cat# 2880S RRID: AB_2106495
pJAK2	Cell Signaling Technology	Cat# 3776S RRID: AB_2617123
JAK2 Total	Cell Signaling technology	Cat# 3230S RRID: AB_2128522
pSTAT3	Cell Signaling Technology	Cat# 9131S RRID: AB_331586
STAT3 Total	Cell Signaling Technology	Cat# 9139S RRID: AB_331757
SOX2	Stemgent	Cat# 09-0024 RRID: AB_2195775
TRA-1-81	Stemgent	Cat# 09-0011 RRID: AB_1512171
NANOG	Stemgent	Cat# 09-0020 RRID: AB_2298294
TRA-1-60	Stemgent	Cat# 09-0010 RRID: AB_1512170
OCT4	Stemgent	Cat# 09-0023 RRID: AB_2167689
SSEA4	Stemgent	Cat# 09-0006 RRID: AB_1512169
<b>Biological Samples</b>		
Brain sec. 1662; 30 year M	UC Irvine Brain Bank	N/A
Brain sec. 1838; 97 year cauc. F	UC Irvine Brain Bank	N/A
Brain sec. 1843; 78 year cauc. M	UC Irvine Brain Bank	N/A
Brain sec. 1919; 61 year cauc. M	UC Irvine Brain Bank	N/A
Brain sec. 2266; 53 year cauc. F	UC Irvine Brain Bank	N/A
Brain sec. 2884; 84 year cauc. M	UC Irvine Brain Bank	N/A
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Accutase	EMD Millipore	SCR005
0.2% Triton X-100	BioRad	1610407
3,3',5,5'-tetra-methylbenzidine	Sigma-Aldrich	860336-1G
4% Paraformaldehyde	Electron Microscopy Sciences	15714-S

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
5% Donkey serum	EMD Millipore	566460
5% Milk solution	BioRad	1706404
Antimycin A	abcam	ab141904
Avidin conjugated Horseradish peroxidase	ThermoFisher	29994
BDNF	Miltenyi Biotec	130-093-811
Chloroform	Sigma-Aldrich	C2432-500ML
CryoStor	Stem Cell Technologies	7930
DAPT	Cayman	13197
FCCP carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone	Sigma-Aldrich	C2920-10MG
Ghrelin peptide	Cayman	15072
Hoechst	ThermoFisher	62249
IWR-endo	Cayman	13659
Laminin basement membrane	Sigma-Aldrich	L2020-1MG
LDN193189	Cayman	11802
Leptin	Peptotech	300-27
Matrigel	Corning	356253
Oligomycin	Sigma-Aldrich	75351-5MG
Purmorphamine	Tocris	4551
Pyruvate	Sigma-Aldrich	P5280-25G
Retinoic Acid	Cayman	11017
ROCK inhibitor Y-27632 (hydrochloride)	Cayman	10005583
Rotenone	Sigma-Aldrich	R8875-1G
SAG Smoothened agonist	Tocris	4366
SB431542	Cayman	13031
Seahorse XF Base medium plus supplements	Agilent	102353-100
Streptomycin	abcam	ab143264
Trizol	ThermoFisher	15596026
Tween-20	Sigma-Aldrich	P9416-100ML
<b>Critical Commercial Assays</b>		
Agencourt AMPure XP beads	Beckman Coulter Genomics	NC9959336
Agilent high sensitivity DNA assay	Agilent	5067-4626
Agilent SureSelect Human Exon kit v4	Agilent	5190-8863
Agilent Total RNA 6000 Nano Kit	Agilent	5067-1511
ELISA Kit for Alpha-Melanocyte Stimulating Hormone (αMSH)	Cloud-Clone	CEA239Hu
EMD Millipore Human Neuropeptide Y ELISA	EMD Millipore	EZHNPY-25K
GoScript Reverse Transcriptase	Promega	A5003
Halt Protease Inhibitor Cocktail	ThermoScientific	78430
Illumina TruSeq stranded mRNA library	Illumina	20020594
Mammalian PER	ThermoScientific	78501
Microelectrode Array Plate, 48 wells	Axion	M768-KAP-48
Nitrocellulose Membrane	BioRad	1620115
NuPAGE Novex Polyacrylamide Gel	ThermoScientific	NP0322BOX
QIAGEN On-Column DNase	QIAGEN	79254
QIAGEN Rneasy Mini Kit	QIAGEN	74104
Seahorse culture plate	Agilent	100777-004
Streptavidin-coated Magnetic Beads	New England Biolabs	S1421S
Super-Script II Reverse Transcriptase	ThermoScientific	18064014

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
SYBR Green Master mix	Applied Biosystems	4309155
Agencourt AMPure XP beads	Beckman Coulter Genomics	NC9959336
Agilent high sensitivity DNA assay	Agilent	5067-4626
Agilent SureSelect Human Exon kit v4	Agilent	5190-8863
Agilent Total RNA 6000 Nano Kit	Agilent	5067-1511
ELISA Kit for Alpha-Melanocyte Stimulating Hormone (αMSH)	Cloud-Clone	CEA239Hu
EMD Millipore Human Neuropeptide Y ELISA	EMD Millipore	EZHNPY-25K
GoScript Reverse Transcriptase	Promega	A5003
Halt Protease Inhibitor Cocktail	ThermoScientific	78430
Illumina TruSeq stranded mRNA library	Illumina	20020594
Mammalian PER	ThermoScientific	78501
Microelectrode Array Plate, 48 wells	Axion	M768-KAP-48
Nitrocellulose Membrane	BioRad	1620115
NuPAGE Novex Polyacrylamide Gel	ThermoScientific	NP0322BOX
QIAGEN On-Column DNase	QIAGEN	79254
QIAGEN Rneasy Mini Kit	QIAGEN	74104
Seahorse culture plate	Agilent	100777-004
Streptavidin-coated Magnetic Beads	New England Biolabs	S1421S
Super-Script II Reverse Transcriptase	ThermoScientific	18064014
SYBR Green Master mix	Applied Biosystems	4309155
Agencourt AMPure XP beads	Beckman Coulter Genomics	NC9959336
Agilent high sensitivity DNA assay	Agilent	5067-4626
Agilent SureSelect Human Exon kit v4	Agilent	5190-8863
Agilent Total RNA 6000 Nano Kit	Agilent	5067-1511
Pierce BCA Protein Assay Kit	ThermoScientific	23225
ELISA Kit for Alpha-Melanocyte Stimulating Hormone (αMSH)	Cloud-Clone	CEA239Hu
EMD Millipore Human Neuropeptide Y ELISA	EMD Millipore	EZHNPY-25K
GoScript Reverse Transcriptase	Promega	A5003
Halt Protease Inhibitor Cocktail	ThermoScientific	78430
Illumina TruSeq stranded mRNA library	Illumina	20020594
Mammalian PER	ThermoScientific	78501
Microelectrode Array Plate, 48 wells	Axion	M768-KAP-48
Nitrocellulose Membrane	BioRad	1620115
NuPAGE Novex Polyacrylamide Gel	ThermoScientific	NP0322BOX
QIAGEN On-Column DNase	QIAGEN	79254
QIAGEN Rneasy Mini Kit	QIAGEN	74104
Seahorse culture plate	Agilent	100777-004
Streptavidin-coated Magnetic Beads	New England Biolabs	S1421S
Super-Script II Reverse Transcriptase	ThermoScientific	18064014
SYBR Green Master mix	Applied Biosystems	4309155
Deposited Data		
RNA-seq data	NCBI: GEO	GEO: GSE95243
Whole-exome sequence data	Sequence Read Archive	PRJNA416010
Experimental Models: Cell Lines		
iPSC line 02iCTR_nTn1	CSMC Stem Cell Core	CS02iCTR_nTn1
iPSC line 03iCTR_nTn1	CSMC Stem Cell Core	CS03iCTR_nTn1
iPSC line 25iCTR_n5	CSMC Stem Cell Core	CS25iCTR_n5

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
iPSC line 80iCTR_Tn3	CSMC Stem Cell Core	CS80iCTR_Tn3
iPSC line 87iCTR_n3	CSMC Stem Cell Core	CS87iCTR_n3
iPSC line 201iCTR_Tn6	CSMC Stem Cell Core	CS201iCTR_Tn6
iPSC line 02iOBS_n4	CSMC Stem Cell Core	CS02iOBS_n4
iPSC line 03iOBS_n3	CSMC Stem Cell Core	CS03iOBS_n3
iPSC line 04iOBS_n9	CSMC Stem Cell Core	CS04iOBS_n9
iPSC line 77iOBS_n3	CSMC Stem Cell Core	CS77iOBS_n3
iPSC line 90iOBS_n1	CSMC Stem Cell Core	CS90iOBS_n1
Oligonucleotides		
See <a href="#">Table S6</a>	N/A	N/A
Software and Algorithms		
2100 Expert Software	Agilent	N/A
ANNOVAR release 2015Dev14	<a href="#">Wang et al. 2015</a>	N/A
Cell Specific Enrichment Analysis	<a href="#">Xu et al., 2014</a>	N/A
DESeq2	Bioconductor	N/A
Dougherty pSI Package for R	CRAN	N/A
Genome Analysis Tool Kit (GATK) v.3.5	Broad Institute	N/A
GraphPad	PRISM	N/A
Integrated Pathway Analysis	QIAGEN	N/A
Maestro AxIS Software v.2.0.2.11	Axion Biosystems	N/A
MetaExpress	Molecular Devices	N/A
R / Rstudio	Comprehensive R Archive Network	N/A
R Scripts used in this study	<a href="#">Github:AndrewRGross</a>	N/A
RSEM v.1.2.20	<a href="#">Li and Dewey, 2011</a>	N/A
STAR v2.5.0	<a href="#">Dobin et al., 2013</a>	N/A
Tissue Specific Enrichment Analysis	<a href="#">Dougherty et al., 2010</a>	N/A

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dhruv Sareen.

[dhruv.sareen@cshs.org](mailto:dhruv.sareen@cshs.org)

Dhruv Sareen  
Cedars-Sinai Medical Center  
8700 Beverly Blvd.  
Los Angeles, CA 90048  
AHSP 8418

**EXPERIMENTAL MODEL AND SUBJECT DETAILS****iPSC Model**

iPSCs were obtained from Cedars-Sinai's iPSC core and cultured in essential 8 (E8) or mTeSR medium prior to differentiation. Twelve lines were differentiated into hypothalamic neurons: seven lines from healthy individuals and five from individuals exhibiting extreme obesity. The sample number, N, here refers to the 12 iPSC lines studied, and was selected to use all five available cell lines from obese individuals, as well as an equivalent number of controls.

**Adult Post-Mortem Brain Sections**

Hypothalamic tissue from 6 post-mortem individuals was obtained as a control. The number of samples was selected to match the number of control and obese-patient-derived iPSC cell lines.

## Subject Details

Obese iPSC lines included five females and two males. Control iPSC lines included three males and three females. Brain sections came from four males and two females. The gender of subjects was mixed to make use of available obese-patient-derived iPSC lines. Sex-specific analyses were performed but discerned no difference in results. With regards to sample size, obtained 5 OBS iPSC lines and hence matched that with 5 CTR iPSC lines. However, since we wished to include lines derived from a variety of parent cell types, we included 7 CTR iPSC lines overall.

Subject	Type	Disease Condition	Sex	Age	Race	Parent cell type
02iCTR_n1	iPSC line	Non-obese	M	51	Unknown	PBMCs
03iCTR_n1	iPSC line	Non-obese	M	34	Unknown	PBMCs
25iCTR_n2	iPSC line	Non-obese	M	76	Unknown	Fibroblasts
80iCTR_n3	iPSC line	Non-obese	F	84	Unknown	PBMCs
87iCTR_n3	iPSC line	Non-obese	F	Unknown	Hispanic	Lymphoblastoid
201iCTR_n6	iPSC line	Non-obese	F	Unknown	Unknown	PBMCs
688iCTR_n5	iPSC line	Non-obese	M	Unknown	Unknown	Lymphoblastoid
02iOBS_n4	iPSC line	Obese	F	45	Caucasian	Lymphoblastoid
03iOBS_n3	iPSC line	Obese	M	53	Caucasian	Lymphoblastoid
74iOBS_n9	iPSC line	Obese	F	36	Caucasian	Lymphoblastoid
77iOBS_n3	iPSC line	Obese	F	15	Black	Lymphoblastoid
90iOBS_n1	iPSC line	Obese	F	18	Hispanic	Lymphoblastoid
1662	Brain sec.	Non-obese	M	30	Unknown	N/A
1838	Brain sec.	Non-obese	F	97	Caucasian	N/A
1843	Brain sec.	Non-obese	M	78	Caucasian	N/A
1919	Brain sec.	Non-obese	M	61	Caucasian	N/A
2266	Brain sec.	Non-obese	F	53	Caucasian	N/A
2884	Brain sec.	Non-obese	M	84	Caucasian	N/A

## METHOD DETAILS

### Ethics Statement and Reprogramming to iPSCs

Human PBMCs were obtained from whole blood draws of healthy volunteers at Cedars-Sinai under the auspices of the Cedars-Sinai Medical Center Institutional Review Board (IRB) approved protocol Pro00028662. The reprogramming of iPSC cell lines and differentiation protocols in the present study were carried out in accordance with the guidelines approved by Stem Cell Research Oversight committee (SCRO) and IRB, under the auspices of IRB-SCRO Protocols Pro00032834 (iPSC Core Repository and Stem Cell Program) and Pro00036896 (Sareen Stem Cell Program). Reprogramming and characterization of PBMCs and fibroblasts from skin punch biopsies and lymphoblastoid cell lines (LCL) was carried out as previously described (Barrett et al., 2014). We employed one clone each of 7 CTR lines and 5 OBS subjects.

Briefly reprogramming was performed with either the Cell Line Nucleofector Kit C (VACA-1004, Lonza) or B cell Nucleofector Kit (VPA-1001, Lonza) using 1.5  $\mu$ g of each episomal plasmid (Addgene) expressing 7 factors: OCT4, SOX2, KLF4, L-MYC, LIN28, SV40LT and p53 shRNA (pEP4 E02S ET2K, pCXLE-hOCT3/4-shp53-F, pCXLE-hUL, and pCXLE-hSK). Patient derived cells ( $1 \times 10^6$  cells per nucleofection) were harvested, centrifuged at 1500rpm for 5 minutes, re-suspended in Nucleofector® Solution with the E-010 program. These nucleofected cells were plated on feeder-independent BD Matrigel growth factor-reduced Matrix (Corning/BD Biosciences, #354230) and cultures maintained at 20% O<sub>2</sub> during the process. Cells were gradually transitioned to reprogramming media (RM) by adding 1 mL RM to the original respective culture media daily for the next 3 days to aid in attachment. Reprogramming media comprises of DMEM/F12, 1% NEAA, 1% GlutaMax, 1% N2, 2% B27, 0.5% Antibiotic-Antimycotic (GIBCO #15240-062), 0.1  $\mu$ M  $\beta$ -mercaptoethanol, 100ng/ml bFGF (Peprotech), 1:1000 (~1000 units) hLIF (Millipore, #LIF1010), 0.5  $\mu$ M PD0325901 (Cayman Chemicals, #13034), 3  $\mu$ M CHIR99021 (Tocris, #4423), 10  $\mu$ M HA-100 (Santa Cruz Biotech, #203072), and 0.5  $\mu$ M A-83-01 (Tocris, #2939). The cells were then maintained in RM 15 days with fresh media every other day. They were then gradually changed to chemically-defined mTeSR®1 medium between 17-20 days post-nucleofection. Individual iPSC colonies appeared between day 25-32 and those with best morphology were mechanically isolated, transferred onto 12-well plates with fresh Matrigel for further expansion and banking (Figure S1).

### iPSC-derived hypothalamic neuron differentiation (iHTN)

For differentiation into iHTNs, iPSCs were accutase-treated and plated as single cells in 6-well Matrigel-coated plates at a density of approx.  $1 \times 10^6$  cells/well in E8 medium with ROCK-inhibitor Y27632 (10  $\mu$ M; Stemgent). The next day iHTN differentiation was initiated

by neuroectoderm differentiation by dual SMAD inhibition using LDN193189 (1  $\mu$ M, Cayman) and SB431542 (10  $\mu$ M, Cayman) and this treatment is carried on for 48 hours in an in-house neural differentiation medium (Table S2). The neural ectoderm specification from hiPSCs was achieved by dual SMAD inhibition with LDN193189, a BMP type I receptor inhibitor of activin receptor-like kinases (ALKs) ALK2 and ALK3, and SB431542, a transforming growth factor-beta 1 (TGF- $\beta$ 1) of ALK-4, -5 and -7 (Chambers et al., 2009). This was followed by Sonic hedgehog activation by Smoothed agonist SAG (1  $\mu$ M, Tocris) and purmorphamine (PMN, 1  $\mu$ M, Tocris) and Wnt signaling inhibition using IWR-endo (10  $\mu$ M, Cayman) from Day 2 to day 9 to direct the cells toward ventral diencephalon with regular media change every 2 days. Shh activation augments a ventral diencephalon forebrain cell fate in the CNS (Bragina et al., 2010; Hu et al., 2016), while activation of Wnt/ $\beta$ -catenin signaling promotes a more posterior brain identity in the CNS. Subsequently, on day 2 after neural conversion of PSCs small molecule pathway modulators of sonic hedgehog (Shh) [smoothed agonist (SAG), purmorphamine (PMN), robotnikinin (R), and cyclopamine (Cy)] and Wnt/ $\beta$ -catenin signaling [CHIR99021 and IWR-1-endo] were screened in different permutations between day 2 and 8 of differentiation to identify a combination that augmented ventral diencephalon hypothalamic cell identity during post-neural ectoderm specification. The combination of Shh signaling – activated by treatment with SAG and PMN – and inhibition of Wnt/ $\beta$ -catenin signaling – via the addition of Wnt/ $\beta$ -catenin pathway blocker IWR-1-endo – promoted the greatest percent of hypothalamic progenitors, based on the observation of NK2 homeobox 1 (Nkx2.1) and homeobox protein orthopedia (Otp; hypothalamic neuron progenitor that specify neuropeptidergic neurons) immunopositive cells at day 9 post-iPSCs. Day 9 to day 14 the cells are slowly made to exit cell cycle using DAPT (10  $\mu$ M, Cayman) in the presence of caudalizing agent retinoic acid (0.01  $\mu$ M, Cayman). On day 14, the cells were treated with Accutase and re-plated onto laminin-coated plates in the presence of maturation medium containing brain-derived neurotrophic factor BDNF (10 ng/mL, Miltenyi) and maintained until day 40. Upon assessing for hypothalamic markers we detected Otp, Rax, NPY (neuropeptide Y; a secreted neuropeptide of the orexigenic NPY neurons), CART (cocaine amphetamine regulated transcript; a neuropeptide produced by the anorexigenic CART neurons),  $\alpha$ -MSH ( $\alpha$ -melanocyte stimulating hormone; a bioactive product of POMC producing neurons), NPYR (neuropeptide Y receptor Y2; receptor for NPY present), GhreR (ghrelin receptor; ghrelin response receptors present in ARC neurons) and MCH (melanin concentrating hormone; orexigenic hypothalamic peptide found in hypothalamic MCH neurons) (Figure 2B). For freezing, Day 20 neurons were kept frozen in CryoStor<sup>®</sup> (Stem cell technologies) and thawed when needed and cultured for a further 20 days with an average of 70  $\pm$  9% viability (Table S5).

## Adult hypothalamic tissue (aHT-UCIBB) processing

### Brain Tissue

Frozen brain tissue was obtained from 6 autopsy donors, 4 males and 2 females, from the University of California, Irvine Brain Bank (UCIBB). Brains used in this study were obtained after informed consent of next-of-kin and with approval from the University of California, Irvine Institutional Review Board (IRB). Autopsy donors were primarily of Caucasian ethnicity, were 67  $\pm$  24 (mean  $\pm$  SD) years of age at the time of death, had an agonal factor status of 0, had their brains collected after a short postmortem interval (PMI) (13.3  $\pm$  8.3 hr), and had no reported medical history of obesity. Approximately 0.6-0.75cm<sup>3</sup> of the hypothalamic region was micro-dissected from each subject for these studies.

### RNA Extractions and Quantification

Frozen brain tissue was manually homogenized with a plastic pestle in a 1.5ml microfuge tube, in the presence of 0.5ml Trizol, and was allowed to incubate at room temperature for 5min. The pestle was rinsed with an additional 0.5ml Trizol, for a total volume of 1ml. 0.2ml of chloroform was then added to the solution, which was vigorously shaken and allowed to incubate at room temperature for an additional 2min. Phase separation was performed by centrifugation (14,000xg, 4°C, 20min), and the aqueous phase containing the RNA was removed by pipette into a new RNase-free tube and was processed further using a column-based RNA extraction kit. RNA processing/cleanup was performed using the QIAGEN RNeasy Mini Kit, including the optional 15min incubation with the QIAGEN On-Column DNase, all according to the manufacturer's instructions. RNA was eluted with 60  $\mu$ L RNase-free water. RNA was quantified and qualified using the Agilent Total RNA 6000 Nano Kit and the Agilent 2100 Bioanalyzer and 2100 Expert Software. RNA Integrity Numbers (RIN) ranged between 5.3-8.1, with an average RIN of 6.6.

### Immunofluorescence

Cells that were subject to immunofluorescence were first fixed using 4% paraformaldehyde (PFA) for 20 minutes and subsequently washed with PBS. After blocking the cells with 5% donkey serum (Millipore) with 0.2% Triton X-100 (Bio-rad) in PBS for a minimum of 2 hours, the cells were then treated with an appropriate concentration of relevant primary antibody combinations (1:250) overnight at 4°C. After thorough washing using PBS with 0.1% Tween-20, the cells are then treated with appropriate species-specific Alexa Fluor-conjugated secondary antibody combinations for 45 minutes (1:500). Hoechst stains were used to mark the nuclei and the cells were then visualized using appropriate fluorescent filters using ImageXpress Micro XLS (Molecular devices).

### Quantitative PCR

Total RNA was isolated using the RNeasy Mini Kit (QIAGEN) and RNA (2  $\mu$ g) was first DNase treated and reverse transcribed to cDNA with oligo(dT) using the Promega Reverse Transcriptase System (Promega). Reactions were performed in three replicates using SYBR Green master mix (Applied Biosystems) using primer sequences specific to each gene on a CFX384 Real Time system (Biorad). Each PCR cycle consisted of 95°C for 10 minutes, 95°C 30 s  $\rightarrow$  58°C for 60 s, for 40 cycles, and 72°C for 5 minutes. Genes of interest were normalized to RPL13A.

### Immunoblots

Cell pellets were collected and lysed (mammalian PER, Thermo scientific + 1x protease inhibitor cocktail, Thermo Scientific) and samples were prepared after protein quantification. We loaded about 15  $\mu$ g protein per lane of a polyacrylamide gel (NuPAGE Novex 4%–12% Bis-Tris Protein Gels). Once the gels were resolved, they were transferred onto nitrocellulose membrane and subsequently blocked in 5% milk solution for a minimum of 2 hours. This was followed by a one-step i-Bind process which treated the membrane with primary antibody, washing and secondary antibody steps (Life technologies). We employed Li-Cor® IRDye secondary antibodies (680 and 800 wavelength infrared dyes) and detection of bands was carried out in a Li-Cor ODyssey CLx imager (Li-Cor).

### RNA sequencing

Library construction was performed using the Illumina TruSeq Stranded mRNA library preparation kit. Total RNA samples were assessed for concentration using the Nanodrop 8000 (Thermo Scientific) and quality using the 2100 Bioanalyzer (Agilent). One microgram of total RNA per sample was used for poly-A mRNA selection using streptavidin-coated magnetic beads. cDNA was synthesized from enriched and fragmented RNA using reverse transcriptase (Super-Script II, Invitrogen) and random primers. The cDNA was further converted into double-stranded DNA, and the resulting dsDNA was enriched with PCR for library preparation. The PCR-amplified library was purified using Agencourt AMPure XP beads (Beckman Coulter Genomics). The concentration of the amplified library was measured with a NanoDrop spectrophotometer and an aliquot of the library was resolved on an Agilent 2100 Bioanalyzer. Sample libraries are multiplexed and sequenced on a NextSeq 500 platform (Illumina) using 75bp single-end sequencing. On average, 29.5 million reads were generated from each sample.

### $\alpha$ -MSH ELISA

We employed the Cloud-Clone Corp. Enzyme-Linked Immunosorbent Assay (ELISA) kit to measure secreted levels of  $\alpha$ -MSH from our cell supernatants. This competitive inhibition enzyme immunoassay technique uses a monoclonal  $\alpha$ -MSH antibody pre-coated microplate which launches a competitive inhibition reaction between biotin-labeled  $\alpha$ -MSH and the unlabeled  $\alpha$ -MSH from standard and samples. An avidin conjugated Horseradish peroxidase helps identify the unbound sites within each sample and the substrate mediated color development is inversely proportional to the concentration of  $\alpha$ -MSH in the sample. A log-log graph was used to quantify the amount of  $\alpha$ -MSH present in each sample.

### NPY ELISA

We employed the EMD Millipore Human Neuropeptide Y ELISA kit to measure secreted NPY levels. This is a sandwich ELISA which captures NPY in the sample by antihuman NPY IgG and immobilizes the resulting complex to wells of a microtiter plate coated with pre-titrated amount of anchor antibodies. The captured NPY then binds to a second biotinylated antibody to NPY followed by conjugation of horseradish peroxidase to the immobilized biotinylated antibodies. NPY is quantified by monitoring horseradish peroxidase activities in the presence of the substrate 3,3',5,5'-tetra-methylbenzidine. The enzyme activity is measured spectrophotometrically by the increased absorbency at 450 nm. The increase in absorbency is directly proportional to the amount of captured NPY.

### Metabolic Phenotyping and Seahorse Respirometry Assay

The Seahorse XF<sup>®</sup>24 Extracellular Flux Analyzer (Seahorse Biosciences) was used to perform mitochondrial stress tests and obtain real-time measurements of oxygen consumption rate (OCR) in cells. iFGEs and iHTNS treated with or without EDCs were seeded in a 24-well Seahorse culture plate at a density of 10,000–15,000 cells/well on Day 14 of differentiation and allowed to differentiate on the plate thereon until Day 40 when the assay was performed. For analysis of OCR, culture media was first exchanged for Seahorse XF Base media (supplemented to 10mM Glucose, 1mM Pyruvate, and 1mM Glutamine, pH 7.4) and cells were allowed to equilibrate for 1 hour at 37°C in a non-CO<sub>2</sub> incubator before performing the assay. Chemical reagents targeted to specific functions of the mitochondria (Sigma) were used at final concentrations as follows: 1  $\mu$ M Oligomycin - an ATP synthase inhibitor, 1  $\mu$ M (FCCP) carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazine - an uncoupling agent, and a mixture of 0.5  $\mu$ M antimycin A - a cytochrome C reductase inhibitor and 0.5  $\mu$ M rotenone - a complex I inhibitor. Results were normalized to protein concentration determined by BCA assay (Thermo Scientific).

### MEA measurements

We employed a 48-well microelectrode array (MEA) plate (Figure 4A) for measurement of neuronal firing in iHTNs. MEA plates were precoated with Laminin and day 14 iHTN progenitors were single-cell dissociated and plated where they were maintained in iHTN maturation medium. Each day since plating cells i.e day 14, measurements were obtained for 10 minutes spans until day 60. The recording conditions were at 37°C using the standard neural setting (Axion Biosystems Maestro Axis software version 2.0.2.11). Recorded spike number per electrode were averaged after disregarding noisy electrodes from analysis.

### Exogenous peptide treatments

The neurons were treated with exogenous ghrelin (10nM) and leptin (100ng/ml) on days 33, 35 and 37 of iHTN differentiation and respective conditioned media was collected on days 35, 37 and 40, i.e., day 2,4 and 7 of treatment.

### Whole Exome Sequencing: Library preparation and sequencing

Sequencing libraries were generated using Agilent SureSelect Human All Exon V4 kit (Agilent Technologies, CA, USA) which targeted 20,965 genes and 334,378 exons, following manufacturer's recommendations. Briefly, a total amount of 1  $\mu$ g genomic DNA per sample was fragmented by a M200 shearing system (Covaris, Massachusetts, USA) to generate 180-280bp fragments. After end-repair, A-tailing, ligation, PCR enrichment and hybridization with biotin labeled probes, library DNA were captured by magnetic beads with streptomycin, followed by indexing PCR. PCR Products were purified using AMPure XP system (Beckman Coulter, Beverly, USA) and quantified using Agilent high sensitivity DNA assay on an Agilent Bioanalyzer 2100 system. Sequencing libraries were loaded on a HiSeq X Ten (Illumina, San Diego, CA) with paired-end 2x150bp sequencing setting to obtain an average sequencing depth of  $\sim$ 43.5M reads. The sequence data have been deposited in the Sequence Read Archive (SRA) with the accession code PRJNA416010.

## QUANTIFICATION AND STATISTICAL ANALYSIS

### Neuron tracing and neurite length measurement

Cell quantification and morphological analysis was performed on images using MetaExpress. The number of cell types for a specific marker was determined as a percentage of Hoechst positive nuclei. For neuronal tracing NeuroLucida was employed and the analysis of neurite length and the distance spanned by the primary neurite (tip of neurite to cell body) was measured in microns.

### Data analysis for RNA seq

Raw reads obtained from RNA-Seq was aligned to the transcriptome using STAR (version 2.5.0) (Dobin et al., 2013)/ RSEM (version 1.2.20) (Li and Dewey, 2011) with default parameters, using a custom human GRCh38 transcriptome reference downloaded from <https://www.gencodegenes.org>, containing all protein coding and long non-coding RNA genes based on human GENCODE version 23 annotation. Differential expression was calculated using the DESeq2 module in R using expression counts. Gene expression for all other observations were normalized by sequencing depth to Transcripts per Million reads (TPM) (Tables S3 and S4). All R scripts used in analysis are available on Github at <https://github.com/Sareen-Lab/HT-Neurons-in-Obesity>. Raw reads were made available on NCBI's GEO portal at accession number GSE95243.

### Spearman Correlation

The Spearman correlation is a measure of the similarity of the rank of two lists: lists of identical order produce a score of 1 and lists with no relationship in order produce a score of 0. Expression data was compared to references from the Genotype-Tissue Expression (GTEx) project database. The highest expressed 10,000 genes from each sample and reference were compared using a Spearman correlation in R using the `rcorr` function. Distant references were filtered out of the expression data for visual clarity. The resulting distance matrix was then exported as a boxplot. The entire R script used to generate these tables and the resulting heatmap can be found on Github at <https://github.com/Sareen-Lab/HT-Neurons-in-Obesity/>.

### Bioinformatics (TSEA, CSEA)

We assessed the similarity of our samples to several human tissues and cell types using the Dougherty pSI tissue identification method (Dougherty et al., 2010; Xu et al., 2014) to identify tissue identity exhibited by the iHTNs. This method predicts a sample's closest tissue identity by calculating the probability of each gene in each set occurring outside of a given tissue. The similarity between a sample and a set of reference cell or tissue is scored types based on the number of highly enriched genes in the sample which have been identified as having a statistically significant association with a given reference (Dougherty et al., 2010). First, a reference expression set is used to assign to each gene a Specificity Index based on the probability of a gene occurring outside of a given tissue (pSI). Since they represent a probability, they are abbreviated as pSI, and increase in significance as they get smaller. This method is performed by first scoring each gene in an expression dataset using the specificity index calculation. These scores represent the probability of a given gene occurring outside of a given tissue by chance. The output of the specificity index calculation is a specificity index table with the same dimensions as the original expression table, but in which expression values have been replaced with pSI values. Then, the pSI values for each gene in a queried set are used to predict the probability of such a set occurring by chance in each of the tissues included in the original reference set.

Scoring all genes in an expression table allows us to assemble list of genes with significant specificity index scores for each reference tissue included in the original expression table. These gene lists represent the genes which have been identified as uniquely representative of a given reference tissue. We can then compare the highest expressed genes in a sample against the gene lists for each reference using another algorithm developed along with the specificity index calculation. This comparison is repeated for each reference four times across four different stringency levels to determine the similarity of the sample against large gene lists of moderate specificity scores as well as small, tightly restrictive gene lists containing genes with very small specificity scores.

In subsequent publications, Dougherty et al. displayed the results of this comparison as a set of nested hexagons which display the comparison algorithm's confidence in the color of the hexagons. This analysis can be performed instantly by submitting highly expressed genes to a form on the Dougherty lab website. The Dougherty lab website allows users to compare their samples to the Genotype-Transcription Expression project (GTEx) 2013 dataset, which they label as the Tissue Specific Expression Analysis (TSEA) and several transcriptomes taken from the BrainSpan Atlas of Developing Human Brain which they label as the Cell Specific Expression Analysis (CSEA). To compare our sample to the currently available GTEx dataset, we downloaded the updated data and repeated their pSI calculation using the R package pSI. We then compared the genes with the top 1000 median expression values

among our iPSC derived neurons and the genes with the top 1000 median expression values among the adult hypothalamus brain sections we sequenced in R to the new pSI table we'd generated and plotted it in a manner like theirs using Cytoscape in [Figure 3](#). The pSI table we generated and the template files for generating the associated hexagonal bullseye plots in cytoscape are included in supplemental data.

Additionally, we submitted our top expressed genes from both iPSC hypothalamus and brain hypothalamus to TSEA and CSEA. CSEA could not detect a signal from either of these gene lists or from the GTEx hypothalamus gene list, so we instead submitted each of these gene lists to TSEA and then submitted those genes which TSEA associated with the brain into CSEA.

#### **Pathway Analysis using Integrated Pathway Analysis**

Pathways which differed in their mean expression between the obese and control samples were identified using Integrated Pathway Analysis (IPA, QIAGEN). The submitted dataset included 8000 genes, as this was the maximum number of rows supported by IPA under our settings. These 8000 genes were selected by ranking all genes based on the p value associated with their differential expression. Fold changes were only included for the 1498 genes with a p value less than 0.1. The remainder were reassigned a log fold change as zero so that IPA would recognize their presence but conservatively assume no difference in expression between obese and control samples. The pathways detected and the fraction of genes with up, down, or indeterminate regulation were formatted in R and plotted in Cytoscape.

Each node in [Figure 5D](#) represents a pathway IPA predicted to be dysregulated. The size of the node correlates to the p value IPA assigned to the pathway. The pathways are arranged clockwise in ascending p value. The fraction of genes in the pathway which were found to be upregulated in our obese samples is reflected in the size of the red wedge. Downregulated genes are represented by the green wedge and genes which were detected but not conclusively up or downregulated are represented in gray. The number of genes common to any pair of nodes is reflected in the thickness of the line connecting those nodes.

#### **Identification and analysis of Single Nucleotide Variants**

The raw reads passed the quality control were aligned by BWA (version 0.7.8) to the human reference genome GRCh37, with an average coverage of 139.5X coverage on targeted regions. The Genome Analysis Toolkit (GATK) version 3.5 was used for variants calling according to GATK Best Practices recommendations ([DePristo et al., 2011](#)). Variants were filtered against public databases and annotated with ANNOVAR (release 2015Dev14) ([Wang et al., 2010](#)). A total of 48 genes potentially associated with obesity were summarized from OMIM Catalog (Term #601665, "Obesity") ([Hamosh et al., 2002](#)) as well as recent studies ([Hendricks et al., 2017](#)). Mutations with 1) mapping coverage more than 30 independent reads, 2) predicted to affect protein function and 3) located within exon regions of obesity related genes were considered as significant candidates and summarized in [Tables 1](#) and [S1](#).

#### **Statistical Analysis of Protein Expression**

Experiments were performed using four independent donor-derived iPSC-derived hypothalamic neuroendocrine cultures (iHTNs). Multiple differentiations and treatments performed in independent experiments and are stated in each figure legend. All data are represented as mean  $\pm$  s.e.m. *p* values < 0.05 were considered significant – \* *p* < 0.05, \*\* *p* < 0.01 and \*\*\* *p* < 0.001. Statistical analyses were performed on GraphPad Prism using student's unpaired t test (with or without Welch's correction) or one-way Analysis of variance (ANOVA) and Bonferroni post-test for multiple comparisons.

#### **DATA AND SOFTWARE AVAILABILITY**

The accession number for the RNA-seq data reported in this paper is GEO: GSE95243. The accession number for the whole genome sequencing data reported in this paper is Sequence Read Archive: PRJNA416010. Any other data are available upon request. All software used is available either commercially or as freeware. All custom codes are available on GitHub at <https://github.com/Sareen-Lab/HT-Neurons-in-Obesity/>.